HEALTH

SL Science Holding Limited's Nasdaq debut has seen significant share price volatility, drawing investor interest in its innovative cell and gene therapies targeting solid tumors, despite inherent biotech risks.

SL Science's shares rose 34% post-Nasdaq listing via SPAC merger, highlighting investor interest in its innovative cell therapy platforms targeting solid tumors and regenerative medicine applications.

Moderna's stock surged over 10% as investors responded positively to its expanding mRNA pipeline, despite ongoing challenges in the post-COVID landscape and mixed analyst opinions on long-term growth.

Merck & Co. shares fell over 2% due to market shifts and sector volatility. Despite challenges, Merck's oncology and vaccine sales provide stability, while strategic acquisitions bolster its pipeline.

Abivax shares surged after new trial data eased cancer concerns linked to its ulcerative colitis drug, obefazimod. The data showed reassuring safety and efficacy results, boosting investor confidence.

The ASX 200 closed nearly unchanged, buoyed by a biotech surge and easing geopolitical tensions, while investors await Chinese manufacturing data and Reserve Bank policy updates.

Neuren Pharmaceuticals' shares rose 36% after its Rett syndrome drug received a positive EU recommendation, marking a significant milestone for the rare disease treatment.

Abbott Laboratories' shares rose due to strong growth in medical devices and diagnostics, driven by innovations like the FreeStyle Libre system, supporting its diversified healthcare portfolio and global expansion.

ACADIA Pharmaceuticals' shares rose 12.65% after European regulators reversed their decision on the company's Rett syndrome drug, trofinetide, paving the way for its marketing in the EU.

SELLAS Life Sciences' stock rose over 11% due to positive developments in its cancer therapy pipeline, highlighting promising clinical trial results and strategic financial management.

Moderna's stock rose over 11% following its Science Day presentation, highlighting an expanded mRNA pipeline beyond vaccines, including oncology and autoimmune programs, signalling a strategic shift towards diversification.

Over 11,000 bottles of chlorthalidone, a blood pressure medication, have been recalled due to a manufacturing defect affecting drug dissolution, potentially impacting treatment effectiveness for patients.

Bio-Techne Corporation's shares rose over 19% due to positive developments in its life sciences tools and diagnostics businesses, reflecting investor confidence in its innovation and market position.

Kymera Therapeutics' stock surged after completing enrollment in a key eczema trial six months early, allowing for an expedited data readout. The company's strategic moves and partnerships continue to drive investor confidence.

AbbVie maintains stability amid pharmaceutical challenges through strategic diversification, focusing on innovative therapies and acquisitions, ensuring resilience despite patent expirations and competitive pressures.

Johnson & Johnson's shares rose after the company raised its 2026 outlook, driven by strong Q1 results and strategic investments in U.S. manufacturing and innovation.

Telix Pharmaceuticals' stock has rebounded from a three-year low, driven by its expanding pipeline of cancer treatments and ongoing regulatory approvals, despite mixed analyst opinions and short-seller interest.

MorningStar Farms recalls Buffalo Chik'n Nuggets and Hot & Spicy Sausage Patties due to potential plastic contamination, urging consumers to discard affected products for a refund.

Oruka Therapeutics' stock rose over 14% due to positive investor sentiment on its clinical pipeline, highlighting the biotechnology sector's potential for substantial returns.

Apogee Therapeutics' stock surged 46% due to positive investor reactions to its clinical advancements, highlighting the biotechnology sector's potential for dramatic market movements.

Definium Therapeutics' stock surged over 54% due to heightened investor interest in its research pipeline and strategic initiatives, reflecting optimism in the biotechnology sector's potential for innovation and growth.

Butterfly Network's stock surged 56% after announcing a partnership with AI startup Midjourney, highlighting a promising future in medical imaging technology despite ongoing profitability challenges.

4DMedical Ltd's stock surged 17.62% as the company expands its respiratory imaging technology across the U.S. and Europe, driven by regulatory clearances and commercial contracts.

Biohaven Ltd. shares rose over 12% due to positive developments in its clinical pipeline, focusing on immunology, neuroscience, and obesity treatments, with analysts projecting significant upside potential.

uniQure's stock surged over 75% after the FDA approved a regulatory path for its AMT-130 gene therapy targeting Huntington's disease, marking a significant milestone for the biotech company.

GSK acquires Nuvalent for $10.6 billion, enhancing its oncology portfolio with promising lung cancer therapies. The deal offers a 40% premium, reflecting Nuvalent's strong clinical pipeline.

Tango Therapeutics' shares rose over 50% following promising Phase 1/2 trial results for a new pancreatic cancer treatment, showing a 92% response rate and potential for significant advancements in oncology.

Tango Therapeutics' stock surged over 32% due to positive developments in its precision oncology pipeline, highlighting investor enthusiasm for its synthetic lethality platform targeting genetically defined cancers.

Moderna faces a pivotal year in 2026, transitioning from pandemic-driven revenues to diversified growth in vaccines and oncology, while managing financial challenges and clinical risks.